Completed PHASE2 INTERVENTIONAL 2-arm NCT01715896

A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

Sponsor: MedImmune LLC

Interventions Golimumab 50 mg Mavrilimumab 100 mg

Updated 8 times since 2017 Last updated: Sep 12, 2016 Started: Mar 31, 2013 Primary completion: Nov 30, 2014 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by MedImmune LLC and has accumulated 8 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MedImmune LLC

Data source: MedImmune LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ashkelon, Israel , Athens, Greece , Baja, Hungary , Balatonfüred, Hungary , Barcelona, Spain , Bardejov, Slovakia , Barranquilla, Colombia , Belgrade, Serbia , Bilbao, Spain , Birkenhead, United Kingdom and 29 more locations